CHICAGO--(BUSINESS WIRE)--Three studies to be presented at the Radiological Society of North America (RSNA) annual meeting report that using bone suppression and computer-aided detection (CAD) software significantly improves the detection of lung nodules on chest X-ray images.
“One should expect many more marks on grossly abnormal lungs than on normal X-rays.”
The research also found CAD performed well on images captured by both portable and upright X-ray machines, and that most false positive marks – the marking of areas on the chest X-ray that are not lung nodules – call radiologists' attention to other important abnormalities, including serious lung diseases, and to medical devices in or on the chest that radiologists would be able to quickly dismiss. Riverain Technologies’ ClearRead software was used in each of the studies.
Lung cancer is the leading cause of cancer death in the United States, claiming more lives than breast, colon and prostate cancer combined, according to the American Cancer Society. X-ray is one of the most common imaging tests; however, ribs and clavicles commonly obscure visibility in the chest, leading to reduced lung cancer detection rates.
Riverain’s ClearRead software suppresses the ribs and clavicles on conventional chest X-ray images, providing radiologists with a clear, unobstructed view of the lungs and exposing abnormalities that might indicate disease. The software is easy to install and adopt, requiring no additional imaging equipment or staffing, and no additional radiation exposure to patients. It can be used to immediately enhance images produced by all X-ray machines throughout a hospital or health system.
Radiologist Detection of Lung Nodules Improved With Bone Suppression Software
In a study at Radbound University Nijmegen Medical Centre (RUNMC), the Netherlands, five attending radiologists and three radiology residents who were not experienced with the Riverain software detected more confirmed lung nodules using ClearRead Bone Suppression™ 2.4 software than when they evaluated the X-ray images on their own.
The radiologists read 300 chest X-ray images with and without bone suppression (111 X-rays with solitary lung nodules and 189 control cases with no nodules). They detected 79 percent of the lung nodules with bone suppression, with approximately 0.3 false positive per image compared to 71 percent detection of lung nodules and 0.21 false positive per image when they reviewed the X-rays on their own.
“The detection of hard-to-find nodules classified as ‘moderately subtle’ and ‘subtle’ was especially improved,” said Steven Schalekamp, M.D., a Ph.D. student in the Department of Radiology of RUNMC. “The radiologists using the bone-suppression software found 26 percent of the lung nodules that were missed entirely on conventional X-ray images.”
Radiologist Performance Also Improved with CAD Software
In a separate RUNMC study involving 300 X-rays and eight readers, the radiologists’ performance also improved when they read the images using Riverain’s CAD software, ClearRead +Detect™ 5.2, which circles suspected lung nodules on bone-suppressed X-ray images. The radiologists accurately detected 79 percent of 111 lung nodules with CAD, versus 73 percent when reviewing the bone-suppressed image without CAD.
The radiologists' false positive rate per image was 0.28 when they used CAD and bone suppression together, and 0.23 when they used bone suppression without CAD. ClearRead +Detect found more than half of the nodules that were missed by the radiologists.
CAD Calls Radiologist Attention to Lung Nodules and Other Lung Diseases and Abnormalities
In a University of Chicago Medical Center study of 608 unselected, consecutive chest X-ray images, (479 X-rays with abnormalities, such as lung nodules, other lung diseases and scars; and 129 X-rays without significant abnormalities), Riverain’s ClearRead +Detect 5.2 CAD software on its own, without radiologist interpretation, detected 72 percent of lung nodules present, or 82 of 114 nodules. The software detected a majority of the nodules regardless of whether the image had been captured using a portable or upright X-ray machine, and even when other abnormalities, including underlying lung disease, were present.
“CAD found the majority of lung nodules in this large study, which simulates a real-world, clinical setting where the use of portable X-ray images and the presence of other abnormalities in patients’ chests make lung nodule detection challenging,” said Steve Worrell, Riverain’s Chief Technology Officer.
The CAD software had 1.3 false positives per image (0.7 on X-rays without significant abnormalities and 1.5 on images with abnormalities). Forty-one percent of the false positives across all X-rays indicated other noteworthy pathologic changes, including pneumonia, a partial or full collapse of a lung (atelectasis), fluid in the lungs (edema), other lung diseases, scars and calcifications. The higher false positive rates than previously reported can be attributed to the additional medical conditions in the lungs.
“This study serves to illustrate that most false positive marks are caused by an abnormal finding. They are only ‘false’ in the sense that they are not cancers,” said Heber MacMahon, M.B., professor of radiology and director of thoracic imaging at the University of Chicago Medical Center. “One should expect many more marks on grossly abnormal lungs than on normal X-rays.”
Nineteen percent of the false positive marks were attributed to medical devices in or on the chest, including catheter ports and electrocardiogram leads. As Dr. Schalekamp's study suggests, the number of false positives actually reported in a clinical setting would be lower because radiologists use their judgment to quickly dismiss automatically produced marks that are caused by medical devices or grossly abnormal tissue.
"We expect that after a learning period, radiologists would be able to dismiss false positive CAD marks very quickly,” Dr. MacMahon said.
“We know that small cancers are often visible in retrospect but were not detected on earlier X-rays,” Dr. MacMahon added. “Routine use of bone suppression and CAD on chest X-rays will reduce the chances of a cancer being missed, thus improving the likelihood of diagnosing unsuspected early-stage disease.”
For more information on Riverain’s bone suppression and CAD technology and related research, visit www.riveraintech.com
An industry leader and technology innovator, Riverain Technologies applies proprietary pattern recognition and machine learning technologies in the creation of software applications for use globally in the health care industry and beyond. The Ohio-based company has developed practical solutions to save and improve the quality of people’s lives through the early detection of disease. The company’s ClearRead software enhances the expert skills of radiologists to improve patient outcomes using standard chest X-ray, without additional radiation dose or procedures for patients. For more information please visit www.riveraintech.com.